The expression of three transgenes in the Engineered DCs leads to significant tumor reduction in both generations of Engineered DCs, showcasing the importance and role of the immune-modulating properties of CD40L, CD93, and CXCL13. The gene discussed is CD93; the disease is neoplasm.